

CDTI Funding Opportunities

Barcelona, 13 of January 2014.

Cecilia Hernández

Head of Department, Health, Bioeconomy, Climate and Natural Resources
Directorate of Promotion and Cooperaton
CDTI

CDTI

Más de 35 años apoyando la I+D+i empresarial

- ✓ Established in 1977.
- ✓ Public Entity (Ministry of Economy and Competitiveness)
- ✓ Business innovation Agency (Spanish Law of Sci. Tech & Innov).

14.000 beneficiary companies



CDTI 2013:

1296 funded companies

586 new companies in CDTI

835 are SMEs

Business RTDI

Technology Modernization
Internationalization

€ 13.325 Mio committed

DO YOU HAVE AN INNOVATIVE IDEA?



CDTI Main Characteristics

- 
- A ballerina with blonde hair, wearing a white tutu and a gold bodice, is captured in a dynamic pose. She is lying on her back on a dark, reflective surface, with her arms raised and hands open, and one leg extended upwards. The background is dark, and the lighting highlights the ballerina's form and the texture of her tutu.
- ✓ Open Calls (except for specific Grants).
 - ✓ Bottom up approach: any applied R&D&I line or sector can be supported (civil technology)
 - ✓ Permanent dialogue.
 - ✓ Coordination & Co-funding with Spanish regions.

CDTI: RTDI Funding Schemes

Seed Start-up Growth Consolidation Competitive Growth


Industrial Research

Experimental Development

Innovation



CDTI: RTDI Funding Schemes



R&D Projects



New or improved process, product or service.– 1 - 3 years

✓ **Requirements:**

- ✓ Trading companies or cooperatives;
- ✓ Univ. Research Centres, Public Hospitals, CRO...subcontracted.
- ✓ Own resources: 30% total budget
- ✓ **Fulfilment incentivising effect.**
- ✓ Minimum budget: **€ 175.000**
- ✓ Eligible costs
 - ✓ Equipment **use**
 - ✓ **Materials**
 - ✓ **Human Resources**
 - ✓ **Subcontracting**
 - ✓ **Indirect and management costs, including audits**

R&D Projects

- ✓ **Funding** up to 75% - 85%
- ✓ Interest rate: **Euribor**
- ✓ Recovery **10 y.** (grace period 2-3 years).
- ✓ **Non-reimbursable parts (up to 25-30%)**
- ✓ Advance payment, up to 25% (200.000€ max without additional guarantees).



Cooperative Projects

- 2 - 6 companies ~
- Min. 500.000 €
- Any partner less than 65%

Non Reimbursable parts

R&D Project Characteristic	SME*	Non SME
Basement	10%	5%
Subcontracting R&D organization (min. 10% of the budget)	15%	10%
International Technology Cooperation	25%**	20%
Specific Regions	20%	20%
*UE Definition		
** 30% if participates for the 1st time.		

Non cumulative.. Calculation on max financial coverage 75%

Technology based companies

Funding



- ✓ Venture Capital for Technology and Innovative **SMES** in Spain.
- ✓ Investments **with private investors** representing the majority in the operation.
- ✓ Contributing with the **sector knowledge** :
 - **4 active co-investment agreements (Agbar, Iberdrola, Repsol and Arteché).**
 - Participation in 6 venture capital entities (2 ICT, **3 BIO-HEALTH**, 1 Industrial Technologies).
 - **BIO-Health Technologies: 4 additional initiatives under negotiation**
- **Investment agreement: 12 years max**
- **Investment period: 4-6 years**

Caixa Innvierte BioMed II

- Commitment € 35 MIO aprox.
- Target companies: Innovative medicines, new diagnosis tools, medical devices, ICT to health.
- Already invested € 3,4 MIO in 3 companies

Inveready Innvierte Biotech II

- Commitment € 17 MIO aprox.
- Target companies: development of new chemical entities or *reprofilings*, molecular diagnosis and gene diagnosis, nutraceuticals production.
- Already invested € 2,41 MIO in 5 companies

Ysios BioFund II Innvierte

- Commitment € 51,8 MIO aprox.
- Target companies: life sciences applied to human health, biotechnology, health devices and ICT to health.

Caixa Innvierte BioMed II

Empresa	Resumen
STAT Diagnostica	Desarrollo de sistemas de diagnóstico molecular y de inmunoensayo totalmente integrados para pruebas clínicas descentralizadas.
Smart Solutions Technologies (Nuubo)	Tecnologías médicas innovadoras, portátiles e inalámbricas para la prevención cardiaca, diagnóstico y rehabilitación. <i>Wearable technologies</i> .
Laboratorios Sanifit	Desarrollo de nuevos compuestos que regulen los procesos de calcificación que suceden en el organismo (calcificaciones cardiovasculares, renales y línea de oral care).

Inveready Innvierte Biotech II

Empresa	Resumen
Althia Health	Desarrollo de nuevas herramientas para el diagnóstico y tratamiento personalizado de las enfermedades oncológicas y precancerosas .
Minoryx Therapeutics	Desarrollo de medicamentos para enfermedades raras o minoritarias, dando prioridad a la enfermedad metabólica genética, que afecta en su mayoría niños y adolescentes.
Palobiofarma	Descubrimiento de nuevos medicamentos basados en la modulación de los receptores de adenosina.
OJER Pharma	Desarrollo de productos dirigidos a mercados dermatológicos, mediante tecnología de vehiculización de activos dermatológicos en forma de geles bioadhesivos.
REVA Health	Desarrollo y distribución de productos OTC altamente innovadores y diferenciales en el mercado de Consumer Health.

Need Internationalisation?



**SMES developments:
International Technology
Promotion Projects**



**Collaborative new
development Project:
multilateral o bilateral
programmes**



HORIZON 2020

Cerca de 80.000 M€ para el nuevo programa de investigación e innovación (2014-2020)

Organisation
European Commission
Research & Innovation

Research and
Innovation

International Projects with Decentralized Funding

Programas internacionales de I+D+i



Internacional
Cooperación
R&D Projects

Non reimbursable part up to 30%



IBEROEKA

Bilateral with:

India, Japan, China, Korea, South Africa

«Unilateral» with:


Algeria, Australia, Egypt, Arabian Emirates
United States of America, Indonesia,
Malaysia, Morocco, Singapore, Thailand,
Taiwan



International Programmes: Main characteristics



Multilateral/ Bilateral/
«Unilateral» Programmes



- ✓ Objective: to achieve an **effective technological cooperation**
- ✓ **Market focused “bottom-up” Industrial R&D Projects**
- ✓ International Consortium: At least **two enterprises** from **two different countries**
- ✓ Procedure*:
 - ✓ **International label / unilateral label by CDTI** of the international dimension
 - ✓ **Domestic funding:** each country funds their own entities
- ✓ Open call, but exceptions,
- ✓ **Balanced consortia**, symmetrical-based collaboration

41 + 3 Countries in Eureka

Alemania

Austria

Bélgica

Bulgaria

Croacia

Chipre

Dinamarca

España

Eslovaquia

Eslovenia

Estonia

Finlandia

Francia

Grecia

Hungría

Islandia

Irlanda

Israel

Italia

Letonia

Lituania

Luxemburgo

Macedonia

Malta

Mónaco

Montenegro

Noruega

Países Bajos

Polonia

Portugal

Reino Unido

República Checa

Rumania

Rusia

San Marino

Serbia

Suecia

Suiza

Turquía

Ucrania

Unión Europea

Países asociados

Corea

Canadá

Sudáfrica



Research performing SMEs?

Joint Programming EUREKA - EU



Devoted to R&D performing SMEs

Market Oriented



Bottom-up

International Cooperation



Cut off dates:

5th March, 2015 y 17th september 2015

Elegibility criteria!



Project leader: R&D performing SME of an Eurostar Country



At least two partners

- Autonomous
- From 2 Eurostar countries

Max 70% budget per country



Under R&D SMEs control

(>50% budget to SMEs)



Max three years

Access to Market in two years*

***Starting Clinical trials**

Eurostars Countries

Austria	Lithuania
Bulgaria	Luxembourg
Belgium	Malta
Croatia	The Netherlands
Cyprus	Norway
Czech Republic	Poland
Denmark	Portugal
Estonia	Romania
Finland	Slovak Republic
France	Slovenia
Germany	South Korea
Greece	Spain
Hungary	Sweden
Iceland	Switzerland
Ireland	Turkey
Israel	United Kingdom
Italy	
Latvia	



Iberoeka Countries

CYTED



21 países

ARGENTINA
BOLIVIA
BRASIL
COLOMBIA
COSTA RICA
CUBA
CHILE
ECUADOR
EL SALVADOR
ESPAÑA
GUATEMALA
HONDURAS
MEXICO
NICARAGUA
PANAMA
PARAGUAY
PERU
PORTUGAL
R. DOMINICANA
URUGUAY
VENEZUELA

IBEROEKA



21 Oficinas Nacionales

...Additional Support



Some data

APPROVED CDTI PROJECTS 2012-2014

HEALTH

CDTI Total funding
January 2012

PROYECTOS	
	268
	284
	330*
(Euros)	216.191.700
CONTRIBUCIÓN (Euros)	156.816.664

Around 8% CDTI funding in this period

*Greater subcontracting rate than average in number of projects as well as budget

PROYECTOS CDTI APROBADOS 2012-JULIO 2014

SALUD

Targeted Diseases	Nr particip	Budget (€)	% Budget
Infecciosas y hematológicas		24.863	10%
Neurológicas/mentales	17	18.914	9%
Cáncer	13.375	19.579	9%
Respiratorias vías altas y bajas	13.24	18.077	9%
Dolor	12.327	16.264	8%
Digestivas, metabólicas, salud y nutrición	10%	11.373	6%
Osteoarticulares y	12	8.371	6%
Cardiovasculares	14	7.941	5%
Oftalmológicas	11	6.665	4%
Inmunológicas	10	6.295	4%
Dermatológicas	6	4.136	3%
Ginecológicas/técnicas reproductivas	10	3.096	2%
Varios/Otros	71	38.612	25%
Total	284	156.817	216.192

Wide range of targeted diseases, covering developments in diagnosis, therapies and prevention

PROYECTOS CDTI APROBADOS 2012-JULIO 2014

SALUD

Technology	Nº particip.	% particip	Contribution CDTI (M€)	Budget (M€)	% out of total budget
Pharma developments	83	29%	83.09	108.75	50%
Biotechnology	70	25%	31.29	43.91	20%
ICT and health equipment	94	33%	27.70	44.30	21%
Nanotech. / materials/ implants	22	8%	6.72	8.76	4%
Bio Engineering / Regenerative medicine	11	4%	6.25	8.32	4%
Several	4	1%	1.76	2.14	1%
Total	284	100%	156.82	216.20	100%

HOW

CAN WE

HELP YOU?

CDTI is a relevant authority to issue binding motivated reports on its funded projects

Issue motivated reports facilitate access to the tax reductions

- A single report for the whole duration of the project
- It provides greater legal security for the companies funded by CDTI
- The report certifies the “ex – ante” contents in RTDI
- A report will be issued to each of the partners of the consortium



CDTI: Participants Support

300 people

✓ Spain



✓ **PI+D+i: NETYWORK** of
150 info desks



<http://www.redpidi.es>

Foreign network Bélgica –

SOST, Japón, Corea, Chile, Marruecos, China, India, México y EEUU. Ampliación de la red finales 2013: Sudáfrica, Egipto, Argelia, Canadá, Argentina, Colombia, Taiwán, Malasia, Australia, Singapur, Indonesia, Tailandia, Emiratos Árabes, Turquía, Israel,





Support & Services: DPC

- Sectors Orientation
- CDTI Funding
- Proposals
- Focus

To keep you informed
our distribution list:
https://www.cdti.es/index.asp?MP=8&ID=1093*614



CENTRO PARA EL
DESARROLLO
TECNOLÓGICO
INDUSTRIAL



Social
Media
Hub



Smartphone/tablet ready

@CDTioficial
www.cdti.net



Thank you very much for your attention!



902 347 434
pidi@cdti.es
www.redpidi.es
www.cdti.es



Cecilia Hernández
Departamento de Salud, Bioeconomía, Clima y Recursos Naturales
Dirección de Promoción y Cooperación
CDTI.

Calle Cid, nº 4. 28001 Madrid.
Teléfono: 915815502